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Abstracts / Biol Blood Marrow Transplant 21 (2015) S322eS354 S327(vs. PBSC) in 146 (62%) recipients. Disease status was early,
intermediate and advanced in 98, 69 and 69 recipients,
respectively. Conditioning intensity was myeloablative (vs.
reduced intensity) in 176 (75%) recipients. GVHD prophylaxis
was MTX based, MMF based and FK in 152, 74 and 10 re-
cipients, respectively. HLA match was 8/8 and 10/10 in 184
(78%) and 179 (76%) pairs, respectively. HLA-DPB1 and MICA
were matched in 44 (19%) and 197 (85%) recipients, respec-
tively. Recipients included 137 (58%) males, 222 (94%) white.
Mean age was 4414 years.
SNPs c.2918+98G, c.3316C, and c.4385C (reference
sequence C4A NG_011638.1) were associated with severe
GVHD and analyzed as a composite variable. Mismatch at 1
of the 3 SNPs occurred in 49 pairs and 187 were matched
across all 3 SNPs. SNP mismatch was associated with
increased risk of severe GVHD in univariable analysis (HR
2.43, 95% CI 1.32-4.47, P¼0.004). There were no signiﬁcant
differences among SNP match and mismatch pairs regarding
HLA match (10/10 vs. <10/10, 8/8 vs. <8/8, DPB1), MICA
match, and patient, disease or transplant characteristics. SNP
mismatch remained signiﬁcantly associated with severe
GVHD in a multivariable analysis (HR 2.54, P¼0.002) after
adjusting for graft source, HLA and MICA mismatch.
Conclusion: GB SNPmismatch is associatedwith a higher risk
of severe acute GVHD independent of the HLA and MICA
match and other clinical risk factors. Avoiding GB SNP
mismatch can potentially reduce the risk of severe acute
GVHD and further investigation in larger cohorts is warranted.473
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Introduction: Killer-cell immunoglobulin-like receptors
(KIRs) are highly polymorphic. Donor KIR2DL1-R 245 poly-
morphism has been associated with stronger signaling
function than others. Our aim is to evaluate this donor
polymorphism in the setting of T cell-repleted haploidentical
hematopoietic stem-cell transplantation (HSCT) with post-
infusion high-dose cyclophosphamide (PiCy).
Patients and Methods: Thirty-nine adult patients who un-
derwent T-cell repleted haploidentical HSCT with PiCy in a
single center were included. Median age was 41 (r: 19-65).
Diagnosis was: Hodgkin’s Lymphoma 11 (28%), Acute
Myeloid Leukemia 14 (35%), Myelodisplastic Syndrome 3
(8%), Acute Lymphoblastic Leukemia 4 (11%), Myeloprolifer-
ative Syndromes 1 (2%), Non-Hodking Lymphoma 4 (11%),
Multiple Myeloma 2 (5%). Conditioning regimen was: mye-
loablative in 16 patients and reduced intensity in 23 patients.
The donor-patient kinshipwas: father in 5 cases (5%), mother
in 10 cases (26%), sibling in 17 cases (44%) and son/daughter
in 7 cases (18%). Donor KIR2DL1 functional allele typing was
retrospectively performed using single nucleotide poly-
morphism assay (Bari et al, Clinical Immunology 2011). KIR
genotype was analyzed by PCR (KIR Typing, Miltenyi Biotec)
using genomic DNA puriﬁed by the (Maxwell 16 Blood DNA
Kit, Promega) from peripheral blood examples. KIR ampli-
cons were visualized with ethidium bromide after agarose
gel electrophoresis. HLA typing was used to identify HLAclass I KIR ligands: HLA-C alleles with a Lys80 residue (C2
alleles), HLA-C with an Asn80 residue (C1 alleles), and HLA-B
alleles with Bw4 and Bw6 speciﬁcity.
Results: Donor KIR2DL1 polymorphismwas: KIR2DL1-R 245
homozygous 26 (66.6%), KIR2DL1-R 245/C245 13 (33,3%),
KIR2DL1-C 245 homozygous 0 (0%). Donor KIR haplotipe was
A-A in 4 (12%) and Bx in 34 (87%). Patient haplotype was A-A
in 7 (18%) and Bx in 32 (82%). Thirteen patients received a
KIR2DL1-R 245 homozygous graft with HLA-C ligand-re-
ceptor mismatch, 13 patients received a KIR2DL1-R 245 graft
with no HLA-C ligand-receptor mismatch and 12 patients
received a KIR2DL1-R 245/KIR2DL1-C245 graft. We did not
ﬁnd event free survival (EFS) differences between patients
who received a KIR2DL1-R 245 homozygous graft or a
KIR2DL1-R 245/KIR2DL1-C245 graft (67% vs 68% p¼0.37).
However, patients who received a KIR2DL1-R 245 graft with
HLA-C ligand-receptor mismatch had a marked tendency to
better event free survival (EFS) compared with those who
received a graft with KIR2DL1-R 245 and no HLA-C ligand-
receptor mismatch (80% vs 100% respectively, p¼0.057) one
year after transplant
Conclusion: Donor KIR2DL1-R 245 allelic polymorphism
associated with KIR HLA-C ligand-receptor mismatch could
affect recipient outcomes after T cell-repleted haploidentical
HSCT with PiCy. These ﬁndings could have signiﬁcant
repercussion for donor selection.474
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Chronic graft-versus-host disease (cGVHD) is a major cause
of morbidity and mortality following allogeneic hemato-
poietic stem cell transplant (AHSCT). Although current
therapies largely target T cell proliferation, in vivo T cell
kinetics of division, death and trafﬁcking have been difﬁ-
cult to evaluate. We employed deuterated water labeling
with subsequent GC-MS/MS enrichment detection to
measure in vivo T cell kinetics after AHSCT in a mouse
model of cGVHD. We investigated CD4 T cell sub-popula-
tion kinetics of cell division, death and trafﬁcking, in non-
target and target tissues of cGVHD. Early in the disease
course, spleens of AHSCT recipients showed a high number
of CD4+ T regulatory (Treg) and T effector memory (Tem)
cells. In vivo cell division kinetics of these two cell types
were high and similar to each other, and slowed as cGVHD
progressed. Meanwhile, Tem cell loss from the spleen was
signiﬁcantly faster than that of Treg cells, likely as a result
of increased trafﬁcking. In support of trafﬁcking was the
ﬁnding of elevated Tem numbers in peripheral blood of
AHSCT recipients despite a relative lymphopenia early in
the disease with subsequent disappearance from the cir-
culation once cGVHD was clinically evident. Furthermore,
overall Tem cell numbers in the host were signiﬁcantly
Figure 1. Total number of CD4+ Treg and Tem cells in the syngeneic vs. allogeneic recipients. Shown are total number of CD4+ Treg and Tem cells in the graft (day 0),
and at subsequent time points following AHSCT for syngeneic (syn) recipients, identical host recipient pairs; and allogeneic (allo) recipients, with minor antigen
mismatch between host and donor with resultant cGVHD induction. Day+14 is a time point early post AHSCT, while day +28 represents well-established cGVHD.
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uted to target rather than non-target tissues. Target sites of
cGVHD (skin, gut and liver) had several fold greater num-
ber of Tem cells compared to controls both early and late in
disease. The number of Tem cells in target sites was
maintained as cGVHD progressed, and the Treg to Tem ratio
in target tissues was signiﬁcantly lower than that of the
controls at all times. Cell division of Tem and Treg cells was
high in the liver, and remained high for the Treg cells as
disease progressed. Meanwhile, Treg cells underwent
faster loss from the liver, likely due to cell death given that
the total number of Treg cells did not change. Our ﬁndings
shed light on in vivo behavior of Treg and Tem cells, T cell
subtypes critical to the biology of cGVHD. Furthermore, our
methodology will be translated to investigate in vivo T cell
kinetics in patients undergoing AHSCT as deuterated water
labeling is safe, not toxic and non-radioactive.475
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Ocular chronic GVHD (cGVHD) is one of the most bother-
some and common long-term complications after allogeneic
HCT. The 2005 NIH cGVHD Consensus Project provided
expert recommendations for diagnosis: dry, gritty, or painful
eyes, cicatricial conjunctivitis, keratoconjunctivitis sicca or
conﬂuent areas of punctate keratopathy in conjunction with
abnormally low Schirmer’s tear test. However these have not
been prospectively validated in patients. The goal of this
analysis was to identify predictive models for ocular cGVHD
diagnosis, disease activity and clinical correlates that could
be feasibly employed by transplant clinicians to assess out-
comes in clinical practice and therapeutic trials. Between2004 and 2013, 210 patients with moderate (n¼57) or severe
(n¼151) cGVHD were enrolled on the NIH/NCI cGVHD cross-
sectional observational study (NCT00092235). Median time
from cGVHD diagnosis to enrollment was 765 (20-6670)
days. Patient-reported outcomes (PROs) and transplant-
clinician-reported outcomes (ClinROs) were gathered:
Schirmer’s, NIH eye score (0-3), Lee cGVHD symptom scale
(dry eye, needs eye drops frequently, and difﬁculty seeing
clearly) (each 0-4) and chief eye symptom intensity scale (0-
10). Participants were examined by ophthalmologists expe-
rienced in diagnosing and treating ocular cGVHD (MBD, RJB),
who conﬁrmed the diagnosis and classiﬁed patients as active
vs. inactive. Univariate analyses and logistic models were
developed to examine the associations among ophthalmol-
ogist assessment, PRO and ClinRO measures. Based on
ophthalmology evaluation, 157 (75%) patients were diag-
nosed with ocular cGVHD; a majority (133/157; 85%) had
active disease. In a multivariable model, the NIH eye score (3
vs. 2 vs.1) (p<0.0001) and lower Schirmer’s (p<0.0001) were
signiﬁcant independent predictors of ocular cGVHD (sensi-
tivity 93.0%, speciﬁcity 92.2%). The Lee dry eye was the
strongest predictor of active ocular cGVHD (p<0.0001)
(sensitivity 68.5%, speciﬁcity 82.6%). The following risk fac-
tors for ocular cGVHD were identiﬁed: related donor
(p¼0.0029) and HLA matched (p¼0.0095) HCT. Oral cGVHD
was strongly associated with the diagnosis of ocular cGVHD
(p<0.0001). NIH eye score and Schirmer’s test are ClinRO
measures that are strongly predictive for diagnosis of ocular
cGVHD, while a single PRO item assessing dry eye symptom
bother had 82.6% speciﬁcity for ocular cGVHD activity. Re-
sults support the use of these items for routine screening and
ocular triage when providing long-term care to allogeneic
HCT survivors. Prospective studies are needed to determine if
a single PRO item assessing dry eye is sufﬁcient for use as a
trial outcome and to guide therapeutic decision-making in
clinical practice. We conﬁrm observations of others that
HLA-matched and related donor transplants are associated
with an increased risk of ocular cGVHD.476
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